51
|
Ladomersky E, Zhai L, Lauing K, Wu M, James CD, Stupp R, Wainwright D. IMMU-22. COMBINATION IMMUNOTHERAPY WITH IDO1 INHIBITION ENHANCES TREATMENT EFFICACY IN MULTIPLE MODELS OF GLIOBLASTOMA MODEL. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
52
|
James CD, Stupp R, Lukas RV, Kalapurakal JA, Akhtar-Zaidi B, Horbinski CM. TMOD-17. BRAIN TUMOR PATIENT DERIVED XENOGRAFT FROM LUNG TUMOR METASTASIS: ESTABLISHMENT AND CHARACTERIZATION. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.1055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
53
|
Piunti A, Morgan M, Bartom E, Louis N, He X, Zhang A, Horbinski C, Marshall S, Rendleman E, Takahashi YH, Misharin A, Abshiru N, Lulla R, Saratsis A, Kelleher N, James CD, Shilatifard A, Hashizume R. PDTM-28. TARGETED INHIBITION OF EZH2 AND BET BROMODOMAIN PROTEINS FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAS. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.792] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
54
|
Park C, Atashi F, Caragher S, Baisiwala S, Lesniak MS, James CD, Ahmed A. DRES-18. EZH2/PRC2-MEDIATED EPIGENETIC PLASTICITY PROMOTES THERAPEUTIC RESISTANCE BY REGULATING STAT3 ACTIVATION GENE NETWORK IN THE GLIOMA STEM CELLS. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
55
|
Bell JB, Eckerdt F, Dhruv HD, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp EM, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, Mazar AP, Vuori K, Kumthekar P, Raizer J, Berens ME, Platanias LC. Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. Mol Cancer Res 2017; 16:32-46. [PMID: 29042487 DOI: 10.1158/1541-7786.mcr-17-0397] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Revised: 09/13/2017] [Accepted: 10/11/2017] [Indexed: 12/16/2022]
Abstract
Mesenchymal (MES) and proneural (PN) are two distinct glioma stem cell (GSC) populations that drive therapeutic resistance in glioblastoma (GBM). We screened a panel of 650 small molecules against patient-derived GBM cells to discover compounds targeting specific GBM subtypes. Arsenic trioxide (ATO), an FDA-approved drug that crosses the blood-brain barrier, was identified as a potent PN-specific compound in the initial screen and follow-up validation studies. Furthermore, MES and PN GSCs exhibited differential sensitivity to ATO. As ATO has been shown to activate the MAPK-interacting kinase 1 (MNK1)-eukaryotic translation initiation factor 4E (eIF4E) pathway and subsequent mRNA translation in a negative regulatory feedback manner, the mechanistic role of ATO resistance in MES GBM was explored. In GBM cells, ATO-activated translation initiation cellular events via the MNK1-eIF4E signaling axis. Furthermore, resistance to ATO in intracranial PDX tumors correlated with high eIF4E phosphorylation. Polysomal fractionation and microarray analysis of GBM cells were performed to identify ATO's effect on mRNA translation and enrichment of anti-apoptotic mRNAs in the ATO-induced translatome was found. Additionally, it was determined that MNK inhibition sensitized MES GSCs to ATO in neurosphere and apoptosis assays. Finally, examination of the effect of ATO on patients from a phase I/II clinical trial of ATO revealed that PN GBM patients responded better to ATO than other subtypes as demonstrated by longer overall and progression-free survival.Implications: These findings raise the possibility of a unique therapeutic approach for GBM, involving MNK1 targeting to sensitize MES GSCs to drugs like arsenic trioxide. Mol Cancer Res; 16(1); 32-46. ©2017 AACR.
Collapse
|
56
|
Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H, O'Halloran T, Raizer J, Mazar AP. Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models. Transl Oncol 2017; 10:669-678. [PMID: 28672195 PMCID: PMC5496477 DOI: 10.1016/j.tranon.2017.06.003] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 05/30/2017] [Accepted: 06/05/2017] [Indexed: 12/15/2022] Open
Abstract
Resistance to chemotherapy remains a major challenge in the treatment of human glioblastoma (GBM). Glycogen synthase kinase-3β (GSK-3β), a positive regulator of NF-κB–mediated survival and chemoresistance of cancer cells, has been identified as a potential therapeutic target in human GBM. Our objective was to determine the antitumor effect of GSK-3 inhibitor 9-ING-41 in combination with chemotherapy in patient-derived xenograft (PDX) models of human GBM. We utilized chemoresistant PDX models of GBM, GBM6 and GBM12, to study the effect of 9-ING-41 used alone and in combination with chemotherapy on tumor progression and survival. GBM6 and GBM12 were transfected by reporter constructs to enable bioluminescence imaging, which was used to stage animals prior to treatment and to follow intracranial GBM tumor growth. Immunohistochemical staining, apoptosis assay, and immunoblotting were used to assess the expression of GSK-3β and the effects of treatment in these models. We found that 9-ING-41 significantly enhanced 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) antitumor activity in staged orthotopic GBM12 (no response to CCNU) and GBM6 (partial response to CCNU) PDX models, as indicated by a decrease in tumor bioluminescence in mouse brain and a significant increase in overall survival. Treatment with the combination of CCNU and 9-ING-41 resulted in histologically confirmed cures in these studies. Our results demonstrate that the GSK-3 inhibitor 9-ING-41, a clinical candidate currently in Investigational New Drug (IND)-enabling development, significantly enhances the efficacy of CCNU therapy for human GBM and warrants consideration for clinical evaluation in this difficult-to-treat patient population.
Collapse
|
57
|
Qi J, Huang T, Hashizume R, Tomita T, James CD, Saratsis A. DIPG-25. IN VITRO AND IN VIVO ANALYSIS OF TENASCIN-C EXPRESSION IN PEDIATRIC BRAINSTEM GLIOMA. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox083.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
58
|
Huang T, Piunti A, Hashizume R, Bartom E, Qi J, Tomita T, James CD, Shilatifard A, Saratsis A. DIPG-24. EPIGENETIC ANALYSIS OF FORMALIN-FIXED PARAFFIN-EMBEDDED PEDIATRIC GLIOMA TISSUE. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox083.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
59
|
Hill VK, Kim JS, James CD, Waldman T. Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing. PLoS One 2017; 12:e0176683. [PMID: 28464039 PMCID: PMC5413031 DOI: 10.1371/journal.pone.0176683] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 04/16/2017] [Indexed: 11/30/2022] Open
Abstract
PTEN is among the most commonly mutated tumor suppressor genes in human cancer. However, studying the role of PTEN in the pathogenesis of cancer has been limited, in part, by the paucity of human cell-based isogenic systems that faithfully model PTEN loss. In an effort to remedy this problem, gene editing was used to correct an endogenous mutant allele of PTEN in two human glioblastoma multiforme (GBM) cell lines– 42MGBA and T98G. PTEN correction resulted in reduced cellular proliferation that was Akt-dependent in 42MGBA cells and Akt-independent in T98G cells. This is the first report of human cancer cell lines in which mutant PTEN has been corrected by gene editing. The isogenic sets of gene edited cell lines reported here will likely prove useful for further study of PTEN mutations in the pathogenesis of cancer, and for the discovery and validation of novel therapeutics targeting the PTEN pathway.
Collapse
|
60
|
Huang TY, Piunti A, Lulla RR, Qi J, Horbinski CM, Tomita T, James CD, Shilatifard A, Saratsis AM. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun 2017; 5:28. [PMID: 28416018 PMCID: PMC5392913 DOI: 10.1186/s40478-017-0436-6] [Citation(s) in RCA: 114] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Accepted: 04/08/2017] [Indexed: 02/08/2023] Open
Abstract
Diffuse midline gliomas (including diffuse intrinsic pontine glioma, DIPG) are highly morbid glial neoplasms of the thalamus or brainstem that typically arise in young children and are not surgically resectable. These tumors are characterized by a high rate of histone H3 mutation, resulting in replacement of lysine 27 with methionine (K27M) in genes encoding H3 variants H3.3 (H3F3A) and H3.1 (HIST1H3B). Detection of these gain-of-function mutations has clinical utility, as they are associated with distinct tumor biology and clinical outcomes. Given the paucity of tumor tissue available for molecular analysis and relative morbidity of midline tumor biopsy, CSF-derived tumor DNA from patients with diffuse midline glioma may serve as a viable alternative for clinical detection of histone H3 mutation. We demonstrate the feasibility of two strategies to detect H3 mutations in CSF-derived tumor DNA from children with brain tumors (n = 11) via either targeted Sanger sequencing of H3F3A and HIST1H3B, or H3F3A c.83 A > T detection via nested PCR with mutation-specific primers. Of the six CSF specimens from children with diffuse midline glioma in our cohort, tumor DNA sufficient in quantity and quality for analysis was isolated from five (83%), with H3.3K27M detected in four (66.7%). In addition, H3.3G34V was identified in tumor DNA from a patient with supratentorial glioblastoma. Test sensitivity (87.5%) and specificity (100%) was validated via immunohistochemical staining and Sanger sequencing in available matched tumor tissue specimens (n = 8). Our results indicate that histone H3 gene mutation is detectable in CSF-derived tumor DNA from children with brain tumors, including diffuse midline glioma, and suggest the feasibility of “liquid biopsy” in lieu of, or to complement, tissue diagnosis, which may prove valuable for stratification to targeted therapies and monitoring treatment response.
Collapse
|
61
|
Wainwright DA, Horbinski CM, Hashizume R, James CD. Therapeutic Hypothesis Testing With Rodent Brain Tumor Models. Neurotherapeutics 2017; 14:385-392. [PMID: 28321824 PMCID: PMC5398994 DOI: 10.1007/s13311-017-0523-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The development and application of rodent models for preclinical testing of novel therapeutics and approaches for treating brain tumors has been a mainstay of neuro-oncology preclinical research for decades, and is likely to remain so into the foreseeable future. These models serve as an important point of entry for analyzing the potential efficacy of experimental therapies that are being considered for clinical trial evaluation. Although rodent brain tumor models have seen substantial change, particularly since the introduction of genetically engineered mouse models, certain principles associated with the use of these models for therapeutic testing are enduring, and form the basis for this review. Here we discuss the most common rodent brain tumor models while directing specific attention to their usefulness in preclinical evaluation of experimental therapies. These models include genetically engineered mice that spontaneously or inducibly develop brain tumors; syngeneic rodent models in which cultured tumor cells are engrafted into the same strain of rodent from which they were derived; and patient-derived xenograft models in which human tumor cells are engrafted in immunocompromised rodents. The emphasis of this review is directed to the latter.
Collapse
|
62
|
Saratsis A, Huang T, Piunti A, Lulla R, Tomita T, James CD, Shilatifard A. PDTB-13. DETECTION OF HISTONE H3 MUTATIONS IN PEDIATRIC GLIOMA VIA TUMOR DNA DERIVED FROM CEREBROSPINAL FLUID. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
63
|
Zhai L, Genet M, Ladomersky E, Lauing K, Wu M, Binder D, Kim L, Rich J, Horbinski C, James CD, Sosman JA, Bloch O, Wainwright DA. Abstract A064: IDO1 expression stratifies glioblastoma patient survival and correlates with dominantly immunosuppressive pathways. Cancer Immunol Res 2016. [DOI: 10.1158/2326-6066.imm2016-a064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: The objective of this study was to evaluate the prognostic significance of the immunosuppressive molecule indoleamine 2, 3-dioxygenase (IDO1) mRNA expression in patients with low-grade glioma (LGG) and glioblastoma (GBM).
Experimental Design: Hi-RNA-seq. Illumina data mined from the cancer genome atlas (TCGA) reflecting 475 LGG (WHO grade II and III) and 172 GBM patients were utilized to characterize the pattern of IDO1 mRNA expression. Kaplan-Meier (KM) survival analysis and multivariate Cox proportional hazards regression were conducted to evaluate the significance of IDO1 expression as a stratification marker in glioma patients. mRNA expression of proinflammatory and immunosuppressive factor genes were also investigated for their correlation with IDO1 mRNA expression. Ivy GAP analysis was further utilized to localize IDO1 mRNA within different GBM anatomic niches.
Results: Expression profiling of the TCGA revealed a distinct pattern of progressively increasing IDO1 mRNA levels correlating with decreased survival both in LGG and GBM patients. In grade III LGG and GBM, IDO1 mRNA expression was significantly decreased when mutant isocitrate dehydrogenase 1 and 2 (mIDH1/2) was coincidently expressed when compared to samples with wild-type IDH1/2 expression (mean difference = 1.51, P < 0.0001 in grade III; mean difference = 2.15, P < 0.01 in GBM). KM analysis and multivariate Cox regression analysis found IDO1 mRNA expression levels to be an independent prognostic factor for survival among LGG (P = 0.0115; HR = 1.68) and GBM (P = 0.0076; HR = 1.82) patients. Pearson's correlation analysis identified significant associations among GBM between IDO1 and the genes encoding immunosuppressive factors including PD-L1 (r = 0.2993, P < 0.0001), PD-L2 (r = 0.4871, P < 0.0001), PD-1 (r = 0.3416, P < 0.0001), CTLA-4 (r = 0.3534, P < 0.0001), STAT3 (r = 0.2366, P = 0.0018), CD39 (r = 0.2691, P = 0.0004), BTLA (r = 0.2981, P < 0.0001), Lag3 (r = 0.2567, P = 0.0007), FoxP3 (r = 0.1865, P < 0.0143) and FGL2 (r = 0.4267, P < 0.0001). Notably, IDO1 mRNA levels were higher in the cellular (1.398 ± 0.1257, mean ± SEM) and necrotic (1.543 ± 0.1489) GBM zones, when compared to infiltrating (0.9303 ± 0.0786) and leading margins (0.9064 ± 0.1224). Additionally, for the IDO1 paralog genes IDO2 and TDO2, which encodes indoleamine 2, 3-dioxygenase 2 and tryptophan dioxygenase respectively, no overall differential expression pattern were observed between different pathological grades nor a significant stratification in LGG and GBM patient survival.
Conclusions: Our data show for the first time that IDO1 mRNA levels can be used as an independent prognostic variable for patients with LGG and/or GBM. Given that ongoing IDO1-targeted immunotherapy clinical trials aim to inhibit enzymatic activity in malignant glioma, our data suggest that targeted subject enrollment may result in a better clinical response to therapy.
Citation Format: Lijie Zhai, Matthew Genet, Erik Ladomersky, Kristen Lauing, Meijing Wu, David Binder, Leo Kim, Jeremy Rich, Craig Horbinski, C. David James, Jeffrey A. Sosman, Orin Bloch, Derek A. Wainwright. IDO1 expression stratifies glioblastoma patient survival and correlates with dominantly immunosuppressive pathways [abstract]. In: Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; 2016 Sept 25-28; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(11 Suppl):Abstract nr A064.
Collapse
|
64
|
Ma Q, Plunti A, Saratsis A, Lulla R, Fangusaro JR, Horbinski C, Goldman S, James CD, Shilatifard A, Hashizume R. PDTB-10. INHIBITION OF RADIATION-INDUCED DNA DAMAGE REPAIR MEDIATED CHROMATIN MODIFICATION BY HISTONE H3 DEMETHYLASE INHIBITOR IN PEDIATRIC BRAINSTEM GLIOMA. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
65
|
Grossauer S, Koeck K, Murphy N, Phillips J, Wrainwright D, Okada H, Mueller S, James CD, Nicolaides T, Petritsch CK. IMST-20. MAPK PATHWAY BLOCKADE PRIMES BRAFV600E MUTANT GLIOMA FOR IMMUNOTHERAPY. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
66
|
Atashi F, Hasan T, Lee G, Guo D, Park C, Lesniak M, James CD, Ahmed A. STMC-16. EZH2-MEDIATED ARL13B REGULATE CILIOGENESIS IN GBM. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
67
|
James CD, Ahmed A, Raizer J, Lesniak M, Horbinski C, Kumthekar P. TMOD-08. PDX MODELING OF RECURRENT GLIOBLASTOMA FOR TESTING SALVAGE THERAPIES. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
68
|
Ladomersky E, Zhai L, Gritsina G, Lauing KL, Genet M, James CD, Wainwright DA. Abstract B018: A novel IDO1 inhibitor combined with targeted immunotherapy durably increases survival in a mouse model of glioblastoma. Cancer Immunol Res 2016. [DOI: 10.1158/2326-6066.imm2016-b018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Glioblastoma (GBM) is the most common primary brain tumor, accounting for 54% of malignant glioma diagnoses. Over the course of the past 30 years, a diagnosis of GBM has remained fatal even after maximum surgical resection, radiotherapy (RT), and chemotherapy, with a median overall survival of 14.6 months. The immunosuppressive microenvironment of GBM is a major contributor to the poor patient outcome. Expression of IDO1, as well as the accumulation of tumor-infiltrating regulatory T cells contribute to the avoidance of immune surveillance. Although current immunotherapies have had some success in extending patient survival, combinatorial treatment approaches addressing both tumor growth and the potent immunosuppression may prove to be more effective. This work aimed to determine the efficacy of a novel, pharmaceutical-grade, blood brain barrier-penetrating small molecule IDO1 inhibitor, BGB-5777, in combination with PD-1 blockade and/or whole brain radiation in an immunocompetent mouse GBM model. METHODS/RESULTS: All mice were intracranially-engrafted 2×105 GL261 (syngeneic to B6 background) cells to recapitulate brain tumors. At 14 days post-intracranial injection (dp-ic.), mice were treated with IgG alone as a control (n = 7), 2Gy RT for 5 days (n = 8), 500 ug (loading dose), followed by three 200 ug maintenance doses given every 3 days, of PD-1 mAb (J43) (n = 8), or 100mg/kg BGB-5777 for 4 weeks (n = 10), with a median overall survival (OS) of 25, 25, 32, and 26.5 days, respectively. Mice treated with dual therapies including RT and PD-1 mAb (n = 10), RT and BGB-5777 (n = 8), or PD-1 mAb and BGB-5777 (n = 9), had a median OS of 30, 39, and 32 days, respectively. All mice treated with mono- or dual-therapy succumbed to tumor burden. In contrast, mice treated with concurrent RT, PD-1 mAb and BGB-5777 (n = 9) showed a significant increase in median OS to 53 days (P<0.0001) with 33% of mice demonstrating a durable survival benefit of more than 150 days. Importantly, mice treated with the triple therapy and co-administered CD4 (n = 9)-, but not CD8 (n = 9)- or NK1.1 (n = 9)-depleting mAb, significantly decreased median OS to 29 days (P<0.001) confirming the requirement of CD4+ T cells for efficacy of this immunotherapeutic approach. CONCLUSION: The data indicate that combining the standard of care agent, RT, with PD-1 blockade and the novel IDO1 inhibitor, BGB-5777, synergistically increases OS in a mouse GBM model. Unexpectedly, CD4+, rather than CD8+ T cells, are required for immunotherapeutic efficacy. Understanding how CD4+ T cells coordinate anti-GBM immunity, the kinetics of PD-1 and IDO1 expression after RT, and determining why CD8+ T cells are dispensable under these conditions, are current areas of active investigation in our laboratory. Ultimately, these data suggest that using radiation to induce potential immunogenicity and/or inflammation in GBM, while co-inhibiting immunosuppression, is a rational and potentially clinically-beneficial pursuit.
Citation Format: Erik Ladomersky, Lijie Zhai, Galina Gritsina, Kristen L. Lauing, Matthew Genet, C. David James, Derek A. Wainwright. A novel IDO1 inhibitor combined with targeted immunotherapy durably increases survival in a mouse model of glioblastoma [abstract]. In: Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; 2016 Sept 25-28; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(11 Suppl):Abstract nr B018.
Collapse
|
69
|
Saratsis A, Huang T, Piunti A, Hashizume R, Bartom E, Tomita T, James CD, Shilatifard A. PDTB-14. INVESTIGATING HISTONE H3 POST-TRANSLATIONAL MODIFICATIONS USING PARAFFIN-EMBEDDED PEDIATRIC GLIOMA TISSUE SAMPLES. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
70
|
Auffinger B, Hasan T, Lee G, Tobias A, Deheeger M, Han Y, Guo D, Lesniak M, James CD, Ahmed A. TMIC-24. THE CONTRIBUTION OF VASCULAR CO-OPTION AND TUMOR-DERIVED ENDOTHELIAL CELLS TO GBM RECURRENCE. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
71
|
Kumthekar P, Ahmed A, Lesniak M, James CD, Horbinski C. TMOD-26. DEVELOPING PATIENT-DERIVED XENOGRAFT MODELS OF METASTATIC CANCER TO THE BRAIN. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
72
|
Zhai L, Genet M, Ladomersky E, Lauing K, Wu M, Binder D, Kim L, Rich J, Horbinski C, James CD, Sosman J, Bloch O, Wainwright D. IMST-39. IDO1 IS PROGNOSTIC FOR GLIOBLASTOMA PATIENT SURVIVAL AND CENTRALLY CORRELATES WITH POTENTLY IMMUNOSUPPRESSIVE MEDIATORS. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
73
|
Ladomersky E, Zhai L, Gritsina G, Lauing K, Genet M, Bloch O, James CD, Wainwright D. IMST-35. IDO1 AND TARGETED IMMUNOTHERAPY IN A MOUSE GLIOBLASTOMA MODEL. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
74
|
Unruh D, Mirkov S, James CD, Horbinski C. TMIC-15. MUTANT IDH1 SUPPRESSES THE PROCOAGULANT AND PROMALIGNANT EFFECTS OF TISSUE FACTOR IN GLIOMAS. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
75
|
Huang T, Alvarez A, Pangeni R, Horbinski C, Lu S, James CD, Raizer J, Brenann C, Sulman E, Finocchiaro G, Tan M, Nishikawa R, Lu X, Nakano I, Hu B, Cheng SY. CSIG-08. A REGULATORY CIRCUIT OF miR-125b/miR-20b AND Wnt SIGNALING CONTROLS GBM PHENOTYPES THROUGH FZD6-MEDIATED PATHWAYS. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|